RSS | Login | Register

ZOLINZA

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare ZOLINZA to:

Generic Name for ZOLINZA

Vorinostat 100mg; caps.

Legal Classification:

Pharmacological Class for ZOLINZA

Histone deacetylase inhibitor.

Manufacturer of ZOLINZA

Merck & Co., Inc.

Indications for ZOLINZA

Refractory cutaneous T-cell lymphoma.

Adult dose for ZOLINZA

Take with food. Swallow whole. 400mg once daily. If not tolerated, may reduce to 300mg once daily, then to 300mg once daily 5 days/week if needed. Continue until disease progression or not tolerated.

Children's dosing for ZOLINZA

<18yrs: not recommended.

Warnings/Precautions for ZOLINZA

Renal or hepatic impairment. Monitor for DVT, pulmonary embolism. Correct electrolyte disturbances before starting therapy. Maintain adequate hydration. Diabetes. Monitor CBC, platelets, blood glucose, serum creatinine, electrolytes (esp. potassium, calcium, magnesium) every 2 weeks for 1^st 2 months, then monthly. Pregnancy (Cat.D). Nursing mothers: not recommended.

Interactions for ZOLINZA

Increased risk of thrombocytopenia and GI bleed with other HDAC inhibitors (eg, valproic acid). Concomitant warfarin: monitor PT, INR.

Adverse Reactions for ZOLINZA

GI upset, fatigue, chills; thrombocytopenia, anemia (may need to modify dose or discontinue); anorexia, dysgeusia, pulmonary embolism, DVT, hyperglycemia.

How is ZOLINZA supplied?

Caps—120

Related Disease:

Lymphoma, cutaneous T-cell

Neoplasms

Phase 3 study of carfilzomib for the treatment of relapsed multiple myeloma

July 21, 2010

Onyx Pharmaceuticals announced that it has begun enrollment in a Phase 3 trial evaluating carfilzomib in combination with Revlimid (lenalidomide) and low dose dexamethasone in patients with relapsed multiple myeloma.

Zuplenz oral soluble film approved for nausea and vomiting

July 06, 2010

The FDA has approved Zuplenz (ondansetron oral soluble film, from Strativa) for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

Phase 3 study of ipilimumab for previously treated metastatic melanoma

June 08, 2010

Bristol-Myers Squibb announced positive results from a Phase 3 study of ipilimumab which demonstrated that overall survival (OS) was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.

Phase 2 study of carfilzomib for the treatment of multiple myeloma

June 07, 2010

Onyx Pharmaceuticals announced interim results from an ongoing Phase 2 study of carfilzomib for the treatment of multiple myeloma.

Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer

June 07, 2010

Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.